VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio ...
Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?
On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...
stocknews8d
3 Genomic Stocks at the Forefront of Precision Medicine
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...
Vertex Pharmaceuticals Unusual Options Activity
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...
stocknews13d
3 Biotech Stocks Revolutionizing Healthcare
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Best Biotech Stocks To Consider – February 03rd
AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...
Promising Biotech Stocks To Follow Today – February 05th
AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...
Nasdaq7d
Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?
However, higher Trikafta/Kaftrio sales are likely to have caused sales erosion of Vertex’s other CF drugs — Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. Vertex and partner C ...
Nasdaq13d
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings)
Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...